Skip to main content
Top
Published in: Cancer Cell International 1/2013

Open Access 01-12-2013 | Primary research

SU6668 suppresses proliferation of triple negative breast cancer cells through down-regulating MTDH expression

Authors: Lu Wang, Zhaozhe Liu, Dongchu Ma, Ying Piao, Fang Guo, Yaling Han, Xiaodong Xie

Published in: Cancer Cell International | Issue 1/2013

Login to get access

Abstract

Background

The multiple tyrosine kinase inhibitors SU6668 have a promising therapeutic effect on the progression of hematological malignancies and some solid tumors. Here, we determined its effect on triple negative breast cancer (TNBC) cells and explored the potential molecular mechanism.

Methods

In this study, MDA-MB-231 cells were treated with SU6668 (15 μM, 30 μM) for 72 h and the change of proliferation was examined by MTT and tablet cloning. DNA ploidy was detected by flow cytometric analysis with PI staining. Double-label immunofluorescence method was used to detect the expression and distribution of MTDH proteins. VEGFR2, HIF-1α, MTDH, E-cadhrein, and SMA expressions were detected by Western bolt assay.

Results

This study showed that SU6668 inhibited the proliferation and induced polyploidization of MDA-MB-231 cells in a dose dependent form. SU6668 exposure increased the distribution of MTDH in cytoplasm and decreased its distribution in nuclei. After the treatment of SU6668, VEGFR2, HIF-1α, MTDH and SMA proteins were down-regulated, while E-cadhrein was up-regulated in MDA-MB-231 cells.

Conclusions

In conclusion, SU6668 exposure maybe induces polyploidization, inhibit EMT and influence the expression of MTDH, which suppresses the proliferation in TNBC cells. MTDH is a key signal protein in downstream of VEGF/HIF-1αpathway in MDA-MB-231 cells, which may be used as the potential target in the treatment of TNBC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Anders CK, Deal AM, Miller CR, Khorram C, Meng H, Burrows E, Livasy C, Fritchie K, Ewend MG, Perou CM, Carey LA: The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer. 2011, 117: 1602-1611. 10.1002/cncr.25746.PubMedCentralCrossRefPubMed Anders CK, Deal AM, Miller CR, Khorram C, Meng H, Burrows E, Livasy C, Fritchie K, Ewend MG, Perou CM, Carey LA: The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer. 2011, 117: 1602-1611. 10.1002/cncr.25746.PubMedCentralCrossRefPubMed
2.
go back to reference Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, Panel members: Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011, 22: 1736-1747. 10.1093/annonc/mdr304.PubMedCentralCrossRefPubMed Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, Panel members: Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011, 22: 1736-1747. 10.1093/annonc/mdr304.PubMedCentralCrossRefPubMed
3.
go back to reference Lu HB, Xie XD, Liu ZZ: Research progress in triple-negative breast cancer. Chinese-German J Clin Oncol. 2010, 4: 239-242.CrossRef Lu HB, Xie XD, Liu ZZ: Research progress in triple-negative breast cancer. Chinese-German J Clin Oncol. 2010, 4: 239-242.CrossRef
4.
go back to reference Su ZZ, Kang DC, Chen Y, Pekarskaya O, Chao W, Volsky DJ, Fisher PB: Identification and cloning of human astrocyte genes displaying elevated expression after infection with HIV-1 or exposure to HIV-1 envelope glycoprotein by rapid subtraction hybridization, RaSH. Oncogene. 2002, 21: 3592-3602. 10.1038/sj.onc.1205445.CrossRefPubMed Su ZZ, Kang DC, Chen Y, Pekarskaya O, Chao W, Volsky DJ, Fisher PB: Identification and cloning of human astrocyte genes displaying elevated expression after infection with HIV-1 or exposure to HIV-1 envelope glycoprotein by rapid subtraction hybridization, RaSH. Oncogene. 2002, 21: 3592-3602. 10.1038/sj.onc.1205445.CrossRefPubMed
5.
go back to reference Li J, Zhang N, Song LB, Liao WT, Jiang LL, Gong LY, Wu J, Yuan J, Zhang HZ, Zeng MS, Li M: Astrocyte elevated gene-1 is a novel prognostic marker for breast cancer progression and overall patient survival. Clin Cancer Res. 2008, 14: 3319-3326. 10.1158/1078-0432.CCR-07-4054.CrossRefPubMed Li J, Zhang N, Song LB, Liao WT, Jiang LL, Gong LY, Wu J, Yuan J, Zhang HZ, Zeng MS, Li M: Astrocyte elevated gene-1 is a novel prognostic marker for breast cancer progression and overall patient survival. Clin Cancer Res. 2008, 14: 3319-3326. 10.1158/1078-0432.CCR-07-4054.CrossRefPubMed
7.
go back to reference Gully CP, Zhang F, Chen J, Yeung JA, Velazquez-Torres G, Wang E, Yeung SC, Lee MH: Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Mol Cancer. 2010, 9: 42-10.1186/1476-4598-9-42.PubMedCentralCrossRefPubMed Gully CP, Zhang F, Chen J, Yeung JA, Velazquez-Torres G, Wang E, Yeung SC, Lee MH: Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Mol Cancer. 2010, 9: 42-10.1186/1476-4598-9-42.PubMedCentralCrossRefPubMed
8.
go back to reference Boutayeb S, Zakkouri FZ, Aitelhaj M, Mesmoudi M, Boutayeb A, Boutayeb W, Mrabti H, Errihani H: Protein tyrosine kinase inhibitors in cancer therapy. Pathol Biol (Paris). 2012, 60: 229-233. 10.1016/j.patbio.2012.05.007.CrossRef Boutayeb S, Zakkouri FZ, Aitelhaj M, Mesmoudi M, Boutayeb A, Boutayeb W, Mrabti H, Errihani H: Protein tyrosine kinase inhibitors in cancer therapy. Pathol Biol (Paris). 2012, 60: 229-233. 10.1016/j.patbio.2012.05.007.CrossRef
9.
go back to reference Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TA, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G, Cherrington: SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 2000, 60: 4152-4160.PubMed Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TA, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G, Cherrington: SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 2000, 60: 4152-4160.PubMed
10.
go back to reference Sessa C, Viganò L, Grasselli G, Trigo J, Marimon I, Lladò A, Locatelli A, Ielmini N, Marsoni S, Gianni L: Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing. Eur J Cancer. 2006, 42: 171-178. 10.1016/j.ejca.2005.09.033.CrossRefPubMed Sessa C, Viganò L, Grasselli G, Trigo J, Marimon I, Lladò A, Locatelli A, Ielmini N, Marsoni S, Gianni L: Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing. Eur J Cancer. 2006, 42: 171-178. 10.1016/j.ejca.2005.09.033.CrossRefPubMed
11.
go back to reference Grosicki S, Grosicka A, Holowiecki J: Clinical importance of angiogenesis and angiogenic factors in oncohematology. Wiad Lek. 2007, 60: 39-46.PubMed Grosicki S, Grosicka A, Holowiecki J: Clinical importance of angiogenesis and angiogenic factors in oncohematology. Wiad Lek. 2007, 60: 39-46.PubMed
12.
go back to reference Van TT, Hanibuchi M, Goto H, Kuramoto T, Yukishige S, Kakiuchi S, Sato S, Sakaguchi S, Dat le T, Nishioka Y, Akiyama S, Sone S: SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model. Respirology. 2012, 17: 984-990. 10.1111/j.1440-1843.2012.02193.x.CrossRefPubMed Van TT, Hanibuchi M, Goto H, Kuramoto T, Yukishige S, Kakiuchi S, Sato S, Sakaguchi S, Dat le T, Nishioka Y, Akiyama S, Sone S: SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model. Respirology. 2012, 17: 984-990. 10.1111/j.1440-1843.2012.02193.x.CrossRefPubMed
13.
go back to reference Montagna E, Bagnardi V, Rotmensz N, Viale G, Renne G, Cancello G, Balduzzi A, Scarano E, Veronesi P, Luini A, Zurrida S, Monti S, Mastropasqua MG, Bottiglieri L, Goldhirsch A, Colleoni M: Breast cancer subtypes and outcome after local and regional relapse. Ann Oncol. 2012, 23: 324-331. 10.1093/annonc/mdr129.CrossRefPubMed Montagna E, Bagnardi V, Rotmensz N, Viale G, Renne G, Cancello G, Balduzzi A, Scarano E, Veronesi P, Luini A, Zurrida S, Monti S, Mastropasqua MG, Bottiglieri L, Goldhirsch A, Colleoni M: Breast cancer subtypes and outcome after local and regional relapse. Ann Oncol. 2012, 23: 324-331. 10.1093/annonc/mdr129.CrossRefPubMed
14.
go back to reference Hu G, Chong RA, Yang Q, Wei Y, Blanco MA, Li F, Reiss M, Au JL, Haffty BG, Kang Y: MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell. 2009, 15: 9-20. 10.1016/j.ccr.2008.11.013.PubMedCentralCrossRefPubMed Hu G, Chong RA, Yang Q, Wei Y, Blanco MA, Li F, Reiss M, Au JL, Haffty BG, Kang Y: MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell. 2009, 15: 9-20. 10.1016/j.ccr.2008.11.013.PubMedCentralCrossRefPubMed
15.
go back to reference Robson EJ, Khaled WT, Abell K, Watson CJ: Epithelial-to-mesenchymal transition confers resistance to apoptosis in three murine mammary epithelial cell lines. Differentiation. 2006, 74: 254-264. 10.1111/j.1432-0436.2006.00075.x.CrossRefPubMed Robson EJ, Khaled WT, Abell K, Watson CJ: Epithelial-to-mesenchymal transition confers resistance to apoptosis in three murine mammary epithelial cell lines. Differentiation. 2006, 74: 254-264. 10.1111/j.1432-0436.2006.00075.x.CrossRefPubMed
16.
go back to reference Wheelock MJ, Johnson KR: Cadherins as modulators of cellula phenotype. Annu Rev Cell Dev Biol. 2003, 19: 207-235. 10.1146/annurev.cellbio.19.011102.111135.CrossRefPubMed Wheelock MJ, Johnson KR: Cadherins as modulators of cellula phenotype. Annu Rev Cell Dev Biol. 2003, 19: 207-235. 10.1146/annurev.cellbio.19.011102.111135.CrossRefPubMed
17.
go back to reference Côme C, Magnino F, Bibeau F, De Santa Barbara P, Becker KF, Theillet C, Savagner P: Snail and slug play distinct roles during breast carcinoma progression. Clin Cancer Res. 2006, 12: 5395-5402. 10.1158/1078-0432.CCR-06-0478.CrossRefPubMed Côme C, Magnino F, Bibeau F, De Santa Barbara P, Becker KF, Theillet C, Savagner P: Snail and slug play distinct roles during breast carcinoma progression. Clin Cancer Res. 2006, 12: 5395-5402. 10.1158/1078-0432.CCR-06-0478.CrossRefPubMed
18.
go back to reference Lombaerts M, Van Wezel T: E-eadherin transcriptional down-regulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Rr J Cancer. 2006, 94: 661-671. Lombaerts M, Van Wezel T: E-eadherin transcriptional down-regulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Rr J Cancer. 2006, 94: 661-671.
19.
go back to reference Alexopoulos E, Gionanlis L, Papayianni E, Kokolina E, Leontsini M, Memmos D: Predictors of outcome in idiopathic rapidly progressive glomerulonephritis (IRPGN). BMC Nephrol. 2006, 7: 1-13. 10.1186/1471-2369-7-1.CrossRef Alexopoulos E, Gionanlis L, Papayianni E, Kokolina E, Leontsini M, Memmos D: Predictors of outcome in idiopathic rapidly progressive glomerulonephritis (IRPGN). BMC Nephrol. 2006, 7: 1-13. 10.1186/1471-2369-7-1.CrossRef
20.
21.
go back to reference Sommer M, Gerth J, Stein G, Wolf G: Transdiferentiation of endothelial and renal tubular epithelial cells into myofibroblast-like cells under in vitro conditions: a morphological analysis. Cells Tissues Organs. 2005, 180: 204-214. 10.1159/000088937.CrossRefPubMed Sommer M, Gerth J, Stein G, Wolf G: Transdiferentiation of endothelial and renal tubular epithelial cells into myofibroblast-like cells under in vitro conditions: a morphological analysis. Cells Tissues Organs. 2005, 180: 204-214. 10.1159/000088937.CrossRefPubMed
22.
go back to reference Wu MP, Young MJ, Tzeng CC, Tzeng CR, Huang KF, Wu LW, Chou CY: A novel role of thrombospondin-1 in cervical carcinogenesis: inhibit stroma reaction by inhibiting activated fibroblasts from invading cancer. Carcinogenesis. 2008, 29: 1115-1123. 10.1093/carcin/bgn077.CrossRefPubMed Wu MP, Young MJ, Tzeng CC, Tzeng CR, Huang KF, Wu LW, Chou CY: A novel role of thrombospondin-1 in cervical carcinogenesis: inhibit stroma reaction by inhibiting activated fibroblasts from invading cancer. Carcinogenesis. 2008, 29: 1115-1123. 10.1093/carcin/bgn077.CrossRefPubMed
23.
go back to reference Li C, Li R, Song H, Wang D, Feng T, Yu X, Zhao Y, Liu J, Yu X, Wang Y, Geng J: Significance of AEG-1 expression in correlation with VEGF, microvessel density and clinicopathologcial characteristics in triple-negative breast cancer. Surg Oncol. 2011, 103: 184-192. 10.1002/jso.21788.CrossRef Li C, Li R, Song H, Wang D, Feng T, Yu X, Zhao Y, Liu J, Yu X, Wang Y, Geng J: Significance of AEG-1 expression in correlation with VEGF, microvessel density and clinicopathologcial characteristics in triple-negative breast cancer. Surg Oncol. 2011, 103: 184-192. 10.1002/jso.21788.CrossRef
24.
25.
go back to reference Zhang X, Zhang N, Zhang MX: Astrocyte elevated gene-1 induces breast cancer proliferation and invasion through upregulating HER2/neu expression. Chin Med J (Engl). 2011, 124: 3546-3550. Zhang X, Zhang N, Zhang MX: Astrocyte elevated gene-1 induces breast cancer proliferation and invasion through upregulating HER2/neu expression. Chin Med J (Engl). 2011, 124: 3546-3550.
26.
go back to reference Sarkar D, Park ES, Emdad L, Lee SG, Su ZZ, Fisher PB: Molecular basis of nuclear factor-kappa B activation by astrocyte elevated gene-1. Cancer Res. 2008, 68: 1478-1484. 10.1158/0008-5472.CAN-07-6164.CrossRefPubMed Sarkar D, Park ES, Emdad L, Lee SG, Su ZZ, Fisher PB: Molecular basis of nuclear factor-kappa B activation by astrocyte elevated gene-1. Cancer Res. 2008, 68: 1478-1484. 10.1158/0008-5472.CAN-07-6164.CrossRefPubMed
Metadata
Title
SU6668 suppresses proliferation of triple negative breast cancer cells through down-regulating MTDH expression
Authors
Lu Wang
Zhaozhe Liu
Dongchu Ma
Ying Piao
Fang Guo
Yaling Han
Xiaodong Xie
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2013
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-13-88

Other articles of this Issue 1/2013

Cancer Cell International 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine